Hinweise zu Qualitätskriterien von Zeitschriften
Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016
CC Licencences
Metriken für Publikationen
Startseite
Login
English
Neuer EVA Antrag
Erweiterte Suche
Durchblättern nach ...
Publikationen im Überblick
HGF Fortschrittsbericht
OA Publikationen
Neue Publikation eintragen
Neue Publikation holen aus...
Fehlende Publikation melden
Ansprechpartner
Hilfe
Bibliometrische Indikatoren
Text
Endnote (RIS)
BibTeX
DOI
 |
|
möglich sobald bei der ZB eingereicht worden ist.
Early detection at different stages of type 1 diabetes.
Diabetes Stoffwechs. Herz 33:74 (2024)
Type 1 diabetes can be identified years before clinical diagnosis based on the detection of multiple islet autoantibodies. Based on this and depending on glycaemic status, a distinction is made between the pre-symptomatic stages 1 and 2. In scientific studies, early detection was associated with significant health benefits at the time of diagnosis and beyond. Teplizumab, an anti-CD3 monoclonal antibody, is the first drug available in the US that has been shown to delay the onset of diabetes in stage 2 by more than 2.5 years. It may soon be available in Europe. This perspective is fuelling the debate about extending population-based screening, but it also requires ethical considerations and a clear public health framework for the medical and psychological care of those affected.
Impact Factor
Scopus SNIP
Altmetric
0.300
0.000
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Review
Schlagwörter
Type 1 Diabetes; Screening; Autoantibodies; Teplizumab; Immunotherapy; Beta-cell Function; B-lymphocyte Depletion; Double-blind; New-onset; Islet Autoantibodies; Children; Risk; Ketoacidosis; Disease; Relatives
Sprache
deutsch
Veröffentlichungsjahr
2024
HGF-Berichtsjahr
2024
ISSN (print) / ISBN
1861-7603
Zeitschrift
Diabetes, Stoffwechsel und Herz
Quellenangaben
Band: 33,
Heft: 5,
Artikelnummer: 74
Verlag
Verl. Kirchheim und Co.
Verlagsort
Postfach 25 24, Mainz, 55015, Germany
Begutachtungsstatus
Peer reviewed
POF Topic(s)
90000 - German Center for Diabetes Research
Forschungsfeld(er)
Helmholtz Diabetes Center
PSP-Element(e)
G-502400-001
WOS ID
001324826200003
Erfassungsdatum
2024-12-09